Johnson & Johnson (J&J) has agreed to acquire Abiomed, a NASDAQ-listed cardiovascular medical technology provider, in an all-cash deal valued at approximately $16.6 billion. The proposed acquisition is expected to further diversify and expand Johnson & Johnson MedTech (JJMT) portfolio into the heart failure and recovery segment through Abiomed’s Impella heart pump platform. Joaquin Duato […]
Hyloris Pharmaceuticals has acquired the global rights from Australia-based Baker Heart and Diabetes Institute (Baker Institute) to CRD-102, a clinical-stage, extended-release Milrinone capsule. CRD-102 is being developed for late-stage heart failure (HF) patients who have an implanted left ventricular assist device (LVAD1) and have developed right HF. According to Hyloris Pharmaceuticals, CRD-102 is the second […]
AstraZeneca has announced that its drug, Forxiga (dapagliflozin), has received approval from the Chinese National Medical Products Administration (NMPA) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) and reduced ejection fraction (HFrEF). This marks a significant step forward in the treatment options available […]
AstraZeneca has secured fast track designation for Farxiga (dapagliflozin) in the US for its use in reducing the risk of hospitalization for heart failure (hHF) or cardiovascular (CV) death in adults after an acute myocardial infarction (MI) or heart attack. The fast track designation for the oral once-daily sodium-glucose co-transporter-2 (SGLT2) inhibitor is based on […]
VisONE heart failure pilot study : Oregon-based medical device developer VisCardia has wrapped up its first-in-human study of the implantable VisONE system for medically refractory heart failure patients who have reduced ejection fraction (HFrEF) and preserved ventricular synchrony. The VisONE Heart Failure pilot trial was a prospective, open-label, multi-center study held at certain European Heart […]
Arena Pharmaceuticals has secured that fast track designation for its drug candidate APD418 from the US Food and Drug Administration (FDA) for the treatment of decompensated heart failure (DHF). APD418 is a β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope. According to the San Diego-based biopharma company, APD418 is a selective antagonist that has been designed […]
Impulse Dynamics, a US medical device company, has secured $80.25 million in a Series D financing round led by medical technology investor Amzak Health Investors for the commercialization of its Optimizer Smart System for heart failure. Optimizer Smart System is an implantable device which has been approved by the US Food and Drug Administration (FDA) […]
Swiss pharmaceutical giant Novartis has announced encouraging results from the TRANSITION phase 4 clinical trial, affirming that Entresto (sacubitril/valsartan) can be safely initiated early in a broad range of patients with heart failure with reduced ejection fraction (HFrEF), shortly after stabilization from an acute heart failure episode. This groundbreaking study underlines the effectiveness of Entresto […]